Jacobo Mintzer, MD, MBA
Dr. Jacobo Mintzer is a psychiatrist with special qualifications in geriatric psychiatry. He has dedicated his career to finding new treatments for Alzheimer’s Disease with a focus on the diagnosis and treatment of the neuropsychiatric symptoms of the disease. Dr. Mintzer is a Professor of Health Sciences, Psychiatry, Neuroscience, and Pathology at the Medical University of South Carolina and is the Chief Research and Innovation Officer at Roper St. Francis Healthcare System in Charleston, SC. Dr. Mintzer is the Principle Investigator for the ADMET program: a National Institute on Aging (NIA) supported program that has worked to define and treat apathy in Alzheimer’s Disease. Dr. Mintzer is former President of the International Psychogeriatric Association, past Treasurer of the American Association for Geriatric Psychiatry, a Board Member of the AARP Global Counsil on Brain Health, a Board Member of the South Carolina Alzheimer’s Association, and has a faculty appointment at Exeter University in the United Kingdom. For ACTC, Dr. Mintzer serves on its steering committee as well as others. Dr. Mintzer is also the contact Principle Investigator for the Life’s end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial supported by the NIA. The project aims to test the efficacy and safety of a combination of THC and CBD cannabinoids for the treatment of hospice-eligible Alzheimer’s patients suffering from agitation.